⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplementary Figure 4 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Izuchukwu F. Okpalanwaka Elizabeth A. Daugherity Amanda L. McCormick Trevor S. Anderson Savanna L. Smith Caryn Lawrence Duke Appiah Devin B. Lowe

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: The bispecific antibody targeting PD-L1 and CD3 enhances the antitumor effects of regorafenib in colon cancer.
KEY EVIDENCE: Supplementary data indicate no observable adverse safety in animals receiving the combination treatment.
APPROACH: The study utilized animal models to assess the safety and efficacy of the regorafenib and bispecific antibody combination.
SIGNIFICANCE: These findings could inform future cancer therapies combining regorafenib with immune-targeting strategies.

Implication

Supplementary figure shows no adverse safety in animals treated with regorafenib and bispecific antibody, suggesting enhanced antitumor effects.

Abstract

Supplementary Figure 4 shows no observable adverse safety in animals after treatment with REG/bsAb.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Okpalanwaka et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d01bf https://doi.org/10.1158/1535-7163.29760638

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 3 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
2Supplementary Figure 9 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
3Supplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
4Supplementary Figure 8 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
5Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025

Supplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
Supplementary Figure 7 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
Supplementary Figure 1 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025